4D Molecular Therapeutics, Inc. Share Price
Equities
FDMT
US35104E1001
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.25 USD | -1.19% | -7.92% | +14.76% |
Sales 2024 * | 6.35M 508M | Sales 2025 * | 7.38M 591M | Capitalization | 1.19B 95.22B |
---|---|---|---|---|---|
Net income 2024 * | -151M -12.09B | Net income 2025 * | -164M -13.13B | EV / Sales 2024 * | 112 x |
Net cash position 2024 * | 480M 38.46B | Net cash position 2025 * | 319M 25.5B | EV / Sales 2025 * | 118 x |
P/E ratio 2024 * |
-7.46
x | P/E ratio 2025 * |
-7.85
x | Employees | 147 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.46% |
Latest transcript on 4D Molecular Therapeutics, Inc.
1 day | -1.19% | ||
1 week | -7.92% | ||
Current month | -27.02% | ||
1 month | -35.18% | ||
3 months | +32.86% | ||
6 months | +122.06% | ||
Current year | +14.76% |
Managers | Title | Age | Since |
---|---|---|---|
Theresa Janke
FOU | Founder | 49 | 11/09/13 |
David Kirn
FOU | Founder | 62 | 11/09/13 |
Uneek Mehra
DFI | Director of Finance/CFO | - | 11/09/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Milligan
CHM | Chairman | 63 | 31/07/20 |
Susannah Gray
BRD | Director/Board Member | 63 | 30/06/20 |
Charles Theuer
BRD | Director/Board Member | 60 | 31/12/15 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.74% | 16 M€ | -8.49% | ||
0.06% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 23.25 | -1.19% | 322,784 |
25/04/24 | 23.53 | -2.97% | 453,265 |
24/04/24 | 24.25 | -2.26% | 290,425 |
23/04/24 | 24.81 | -5.99% | 565,556 |
22/04/24 | 26.39 | +4.51% | 484,648 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.76% | 1.19B | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- FDMT Stock